In a nutshell
As the world grapples with geo-political tensions fuelling global inflation and the near-term economic outlook trend downwards, we remain cautious when navigating the market and continue to focus on value creation efforts for our portfolio companies.
In the past quarter, EDBI’s portfolio companies continued to strive and thrive, with the following new developments:
- New premises in Singapore: WalkMe officiates APAC headquarters, Ambiq opens a Technology Design Centre and MiRXES ushers in Southeast Asia’s largest industrial 4.0 in-vitro diagnostic manufacturing facility
- Accomplishments by our portfolio companies: Esco Aster, a spin-off from Esco Lifesciences Group prepares to scale up current cultivated meat manufacturing capacity in Singapore after being the world’s first to receive the ISO 22000 food safety certification, Us2.ai’s automated clinical workflow tool receives the CE mark clearance and Joby Aviation attains the Federal Aviation Administration’s Part 135 certification
- New partnerships with Voyager Innovations, RVAC Medicines, Neuron Mobility, Aspen Neuroscience and DataStax
